Outcome of different nevirapine administration strategies in preventing mother-to-child transmission (PMTCT) programs in Tanzania and Uganda

MedGenMed Medscape General Medicine

Volumn 8, Issue 2, 2006, Pages

  Karcher, Heiko ^e   Kunz, Andrea ^e   Poggensee, Gabriele ^a   Mbezi, Paulina ^b   Mugenyi, Kizito ^c   Harms, Gundel ^d  

^a ROBERT KOCH INSTITUTE   (Germany)

^b Elderly and Children   (Tanzania)

^c Financial Systems Development Section   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CLINICAL OBSERVATION; CLINICAL PROTOCOL; CONTROLLED STUDY; COUNSELING; DRUG SELF ADMINISTRATION; EDUCATION; FEMALE; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MATERNAL AGE; MULTIVARIATE ANALYSIS; PREGNANCY; RELIGION; TANZANIA; TREATMENT OUTCOME; UGANDA; VIRUS TRANSMISSION; COMPARATIVE STUDY; DISEASE TRANSMISSION;

ADULT; ANTI-HIV AGENTS; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HUMANS; NEVIRAPINE; PREGNANCY; TANZANIA; UGANDA;

EID: 33645778342     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: 10.1186/1758-2652-8-2-12     Document Type: Article

References (25)

1. Guay LA, Musoke P, Fleming T, et al. Intraparturn and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV- 1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;3 54:795-802.
2. Fowler MG, Mofenson L, McConnell M. The interface of perinatal HIV prevention, antiretroviral drug resistance, and antiretroviral treatment: what do we really know? J Acquir Immune Defic Syndr. 2003;34:308-311.
3. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HlV-1 vertical transmission (HIVNET 012). AIDS. 2001;15:1951-1957.
4. Eshleman SH, Jackson JB. Nevirapine resistance after single dose prophylaxis. AIDS Rev. 2002;4:59-63.
5. Cunningham CK, Chaix ML, Rekacewicz C, et al. Development of resistance mutations in women receiving standard antiretroviral. therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis. 2002; 186:181-188.
6. Morris L, Pillay C, Chezzi C, et al. Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine. AIDS. 2003; 17:1698-1700.
7. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004;351:229-240.
8. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection infants. Guidelines on care, treatment and support for women living with HIV/AIDS and their children in resource-constrained settings. Geneva: WHO, 2004. Available at: http://www.who.inVMv/pub/mtct/en/arvdrugswomenguidelinesfinal.pdf Accessed March 8, 2005.
9. HIV/AIDS/STI Surveillance Report. National AIDS Control Programme, Ministry of Health, Tanzania. Report Number 17, March 2003.
10. HIV/AIDS Surveillance Report, STD/AIDS Control Programme, Ministry of Health, Kampala, Uganda, June 2003.
11. Wiktor SZ, Ekpini E, Nduati RW. Prevention of mother-to-child transmission of HIV-1 in Africa. AIDS. 1997; 11 (suppl B): S79-S87.
12. Temmerman M, Quaghebeur A, Mwanyumba F, Mandaliya K. Mother-to-child HIV transmission in resource poor settings: how to improve coverage? AIDS. 2003; 17:1239-1242.
13. Stringer EM, Sinkala M, Stringer JS, et al. Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia. AIDS. 2003;17:1377-1382.
14. Malonza IM, Richardson BA, Kreiss JK, Bwayo JJ, Stewart GC. The effect of rapid HIV-1 testing on uptake of perinatal HIV-1 interventions: a randomized clinical trial. AIDS. 2003; 17:113-118.
15. Farquhar C, Kiarie JN, Richardson BA, et al. Antenatal couple counseling increases uptake of interventions to prevent HIV-1 transmission. J Acquir Immune Defic Syndr. 2004;37:1620-1626.
16. Perez F, Mukotekwa T, Miller A, et al. Implementing a rural programme of prevention of mother-to-child transmission of HIV in Zimbabwe: first 18 months of experience. Trop Med hit Health. 2004;9:774-783.
17. Quaghebeur A, Mutunga L, Mwanyumba F, Mandaliya K, Verhofstede C, Temmerman M. Low efficacy of nevirapine (HlVNET012) in preventing perinatal HIV-1 transmission in a real-life situation. AIDS. 2004; 18:1854-1856.
18. Stringer JS, Sinkala M, Stout JP, et al. Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings. J Acquir Immune Defic Syndr. 2003;32:506-513.
19. Ekouevi DK, Leroy V, Viho A, et al. Acceptability and uptake of a package to prevent mother-to-child transmission using rapid HIV testing in Abidjan, Cote d'lvoire. AIDS. 2004; 18:697-700.
20. Kiarie JN, Kreiss JK, Richardson BA, John-Stewart GC. Compliance with antiretroviral regimens to prevent perinatal HIV-1 transmission in Kenya. AIDS. 2003; 17:65-71.
21. Gaillard P,,Melis R, Mwanyumba F, et al. Vulnerability of women in an African setting: lessons for mother-to-child HIV transmission programmes. AIDS. 2002; 16:937-939.
22. Manzi M, Zachariah R, Teck R, et al. High acceptability of voluntary counselling and HTV-testing but unacceptable loss to follow up in a prevention of mother-to-child HIV transmission programme in rural Malawi: scaling-up requires a different way of acting. Trop Med Int Health. 2005; 10: 1242-1259.
23. Centers for Disease Control and Prevention (CDC). Introduction of routine HIV testing in prenatal care-Botswana, 2004. MMWR Morb Mortal Wkly Rep. 2004;53:1083-1086.
24. Van't Hoog AH, Mbori-Ngacha DA, Marum LH, et al. Preventing mother-to-child transmission of HIV in Western Kenya: operational issues. J Acquir Immune Defic Syndr. 2005;40:344-349.
25. Kironde S, Lukwago J, Ssenyonga R. Scaling the frontier - should traditional birth attendants also be used to provide nevirapine for PMTCT in Uganda? Afr Health Sci. 2003;3:102-103.